- Home
- ODD vs ZLAB Comparison
ODD vs ZLAB Comparison
Compare ODD & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- ZLAB
- Stock Information
- Founded
- ODD 2018
- ZLAB 2013
- Country
- ODD Israel
- ZLAB China
- Employees
- ODD N/A
- ZLAB N/A
- Industry
- ODD
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- ZLAB Health Care
- Exchange
- ODD Nasdaq
- ZLAB Nasdaq
- Market Cap
- ODD 3.8B
- ZLAB 3.6B
- IPO Year
- ODD 2023
- ZLAB 2017
- Fundamental
- Price
- ODD $71.72
- ZLAB $34.55
- Analyst Decision
- ODD Buy
- ZLAB Buy
- Analyst Count
- ODD 8
- ZLAB 4
- Target Price
- ODD $59.00
- ZLAB $47.37
- AVG Volume (30 Days)
- ODD 1.2M
- ZLAB 1.0M
- Earning Date
- ODD 08-06-2025
- ZLAB 08-05-2025
- Dividend Yield
- ODD N/A
- ZLAB N/A
- EPS Growth
- ODD 45.36
- ZLAB N/A
- EPS
- ODD 1.74
- ZLAB N/A
- Revenue
- ODD $703,488,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- ODD $24.46
- ZLAB $44.07
- Revenue Next Year
- ODD $20.26
- ZLAB $49.13
- P/E Ratio
- ODD $41.30
- ZLAB N/A
- Revenue Growth
- ODD 26.83
- ZLAB 43.72
- 52 Week Low
- ODD $32.71
- ZLAB $16.01
- 52 Week High
- ODD $79.18
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- ODD 55.62
- ZLAB 49.05
- Support Level
- ODD $69.63
- ZLAB $36.36
- Resistance Level
- ODD $74.50
- ZLAB $44.34
- Average True Range (ATR)
- ODD 2.65
- ZLAB 1.45
- MACD
- ODD -1.15
- ZLAB -0.16
- Stochastic Oscillator
- ODD 25.84
- ZLAB 39.20
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.